Diagnosing Pulmonary Embolism with CTPA

Key Differences Between CTPA and CT Chest with Contrast

The American College of Radiology recommends CTPA as the first-line imaging test for diagnosing pulmonary embolism due to its higher sensitivity and specificity compared to standard CT chest with contrast, with acquisition timing optimized for peak pulmonary arterial enhancement 1, 2
CTPA includes specialized reconstructions, multiplanar reformations, and 3D renderings designed to evaluate the pulmonary arterial tree, which are essential elements not routinely included in standard CT chest protocols 1, 2
CTPA protocols are optimized for pulmonary arterial visualization, with parameters adjusted for optimal contrast bolus timing and reduced motion artifacts, resulting in high diagnostic accuracy with sensitivity of 83% and specificity of 96% for PE diagnosis 2, 3

The American College of Radiology recommends CTPA as the first-line imaging test for patients with suspected PE who have either high pretest probability or intermediate/low probability with positive D-dimer, allowing for accurate diagnosis and treatment decisions 2
CTPA can identify alternative causes of symptoms when PE is not present, providing additional diagnostic value beyond PE exclusion, and can also identify signs of right ventricular dysfunction that have prognostic significance and may influence treatment decisions 1, 2, 4
The negative predictive value of CTPA is very high, allowing clinicians to safely withhold anticoagulation after a negative study, with a negative predictive value of 96% for low clinical probability and 89% for intermediate probability 3

CTPA delivers a higher radiation dose compared to other imaging modalities, which may be a consideration especially in young women due to breast tissue exposure, with a radiation dose of 3-10 mSv 3
CTPA requires intravenous iodinated contrast, limiting its use in patients with severe renal dysfunction or contrast allergies, and can detect small subsegmental emboli, though the clinical significance and need for treatment of isolated subsegmental PE remains controversial 4, 3, 5

CTPA has a sensitivity of ~83 % and specificity of ~96 % for detecting pulmonary embolism, providing reliable visualization of pulmonary arteries down to the subsegmental level【6】.
Negative predictive value (NPV) of CTPA depends on pre‑test clinical probability:
- Low clinical probability → NPV ≈ 96 %【6】
- Intermediate clinical probability → NPV ≈ 89 %【6】
- High clinical probability → NPV ≈ 60 %【6】
Three‑month recurrence of venous thromboembolism after a negative CTPA is 1.1 %, comparable to the 0.9 % recurrence after a negative conventional pulmonary angiography【7】【8】【9】.

A high‑quality negative CTPA safely excludes pulmonary embolism in most patients, eliminating the need for further PE‑specific investigations or treatment【7】【8】【9】.
In patients with low or intermediate clinical probability, anticoagulation can be withheld after a negative CTPA【6】.
When clinical suspicion is high but CTPA is negative, additional testing (e.g., repeat imaging or alternative modalities) should be considered, because the NPV falls to ~60 % in this group【6】.

Meticulous contrast timing and acquisition protocols are essential to achieve diagnostic performance comparable to published series【7】【8】【9】.
A small proportion of CTPA examinations are technically unsatisfactory, underscoring the need for quality assessment【7】【8】【9】.
Only good‑quality negative CTPA studies can be relied upon to safely exclude pulmonary embolism【7】【8】【9】.

Ventilation‑perfusion (V/Q) scanning is the preferred alternative for patients in whom CTPA is contraindicated (e.g., severe renal impairment, contrast allergy, pregnancy)【6】.
V/Q scanning offers lower radiation exposure and avoids iodinated contrast, making it a safer option in the above populations【6】.

Evidence level not specified in the cited sources.

In patients with low pre‑test clinical probability, a negative CTPA has a negative predictive value (NPV) of ≈ 96%; this falls to ≈ 89% for intermediate probability and to only ≈ 60% for high‑probability patients, indicating a substantial risk of missed PE in the latter group【10】.
CT pulmonary angiography demonstrates an overall sensitivity of about 83% and specificity of 96% for detecting acute pulmonary embolism, meaning roughly 17% of true PE cases may be missed【10】.

When clinical judgment (high pre‑test probability) conflicts with a negative CTPA, clinicians should pursue additional testing rather than rely on the scan alone【10】.
For patients with high clinical probability but a negative CTPA, recommended next steps include lower‑extremity venous ultrasound, repeat CTPA with optimized technique, or ventilation‑perfusion (V/Q) scanning before definitively excluding PE【10】.

CT pulmonary angiography performed for suspected acute PE can miss chronic thromboembolic pulmonary hypertension, a potentially fatal late sequela of PE【11】.
Radiologists should actively assess CTPA images for signs of pre‑existing CTEPH (e.g., webs, bands, or mosaic perfusion) when evaluating patients with suspected acute PE【10】.

In prospective follow‑up studies where anticoagulation was withheld after a negative CTPA, the false‑negative rate for subsequent venous thromboembolism was 0.4% (95 % CI 0.2–1.3 %), indicating that withholding treatment is generally safe in appropriately selected patients【12】.

Ventilation‑perfusion scanning should be considered in patients who cannot undergo CTPA (e.g., severe renal impairment, contrast allergy, or pregnancy) and provides lower radiation exposure while maintaining diagnostic utility【10】.